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Abstract
Ezh2 is a histone trimethyltransferase that silences genes mainly via catalyzing trimethylation of histone 3 lysine 27
(H3K27Me3). The role of Ezh2 as a regulator of gene silencing and cell proliferation in cancer development has been
extensively investigated; however, its function in heart development during embryonic cardiogenesis has not been well
studied. In the present study, we used a genetically modified mouse system in which Ezh2 was specifically ablated in the
mouse heart. We identified a wide spectrum of cardiovascular malformations in the Ezh2 mutant mice, which collectively led
to perinatal death. In the Ezh2 mutant heart, the endocardial cushions (ECs) were hypoplastic and the endothelial-to-
mesenchymal transition (EMT) process was impaired. The hearts of Ezh2 mutant mice also exhibited decreased
cardiomyocyte proliferation and increased apoptosis. We further identified that the Hey2 gene, which is important for
cardiomyocyte proliferation and cardiac morphogenesis, is a downstream target of Ezh2. The regulation of Hey2 expression
by Ezh2 may be independent of Notch signaling activity. Our work defines an indispensible role of the chromatin
remodeling factor Ezh2 in normal cardiovascular development.
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Introduction
The development of normal cardiac structure/function is
essential for the survival of mammalian embryo. Cardiac
development is a complex process that proceeds through cardiac
remodeling, endocardial cushion (EC) development, and outflow
tract formation. Disturbance of one or more of these processes
may lead to cardiac structural malformations, i.e., congenital heart
defects (CHDs), which are the most common of all human birth
defects [1]. EC formation, which involves endocardial cell
activation, endothelial-to-mesenchymal transition (EMT), and
the proliferation, migration and subsequent invasion of mesen-
chymal cells into the acellular matrix (the cardiac jelly) to
eventually form mature and functional ECs, is a critical process
associated with atrioventricular septation and outflow tract
formation. Although a number of transcription factors and
signaling molecules were shown to be involved in normal heart
development [2,3,4], the genetic network underlying development
of CHDs, including deficiency in EC formation, remains an issue
of intense interest.
Epigenetic systems that activate/silence gene expression are
emerging as a key regulator in cell fate determination, stem cell
pluripotency maintenance, and normal embryogenesis. The two
fundamental epigenetic systems that have been extensively studied
and have been shown to regulate gene activity are the chromatin
remodeling Polycomb group (PcG) proteins including the poly-
comb repressive complex (PRC) 1 and 2, and the Trithorax-group
(TrxG) complexes including the SWI/SNF complex. The PRC
mainly catalyzes trimethylation of H3 lysine 27 (H3K27Me3) for
gene silencing, whereas the TrxG complexes catalyzes trimethyla-
tion of H3 lysine 4 (H3K4Me3) for activation; both groups
preferentially target the histone 3 on CpG islands that are present
in the cis-regulatory region of a broad spectrum of genes [5,6,7].
PRC2 contains Ezh2, the only enzymatically active subunit in
PRC2 that catalyzes H3K27Me3 via its SET domain, although to
complete this enzymatic reaction requires physical interaction of
Ezh2 with its partners [8,9,10]. The trimethylation of H3K27
provides a platform to recruit PRC1, facilitating silencing of the
target genes. Thus, catalysis of H3K27Me3 by Ezh2 is a critical
step that enables PcG proteins to accomplish their repressive
function. In addition to its well-defined suppressive activity, Ezh2
may act as a co-activator. For instance, Ezh2 potentiated target
gene activity via direct physical association with the estrogen
receptor and b-catenin [11], and with RelA/RelB [12]. The
positive impacts exerted by Ezh2 on these target genes were
independent of its histone methyltransferase activity, i.e., SET
domain. In addition, Ezh2-catalyzed H3K27Me3 has also been
proposed to play a role in either activating or maintaining the
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findings therefore suggest that Ezh2 exhibits dual functions of
either activation or inhibition, which may be context-dependent.
The role of Ezh2 as a regulator of gene silencing, cell
proliferation and embryonic stem cell identity has been previously
studied [14,15]. For instance, overexpression of Ezh2 specifically in
the mammary epithelial cells promoted epithelial growth [16],
whereas decrease of Ezh2 in a numerous cell lines resulted in
defective cell division [17,18]. Ezh2 was also shown to be involved
in modulation of apoptosis. For example, Ezh2 suppressed E2F1-
mediated apoptosis via epigenetically repressing expression of Bim,
a pro-apoptotic factor that was a downstream target of E2F [19].
In addition, Ezh2 was required for normal murine embryogenesis,
as demonstrated by early embryonic lethality of Ezh2
2/2 embryos
[20]. Indeed, Ezh2 contributed to the development of a number of
tissues/organs, such as the development of B cells, hair follicles,
and limbs [21,22,23]. However, whether Ezh2 has crucial
functions in cardiovascular development during embryogenesis
has not been well investigated, although the detection of Ezh2
mRNA in the developing mouse embryonic heart at E9.5 [24]
pointed to its potential role in cardiogenesis. This is in a sharp
contrast to the well-defined roles of SWI/SNF complex compo-
nents such as Baf60c and Brg1 in cardiac morphogenesis [25,26].
In this study, we conditionally knocked out Ezh2 in murine
hearts using mice with floxed Ezh2 alleles and Nkx2.5-cre, the latter
which is a cardiac-specific cre expression line in which the cre
recombinase expression is driven by the endogenous Nkx2.5
promoter [27]. This cre is active in the cardiac progenitor cells and
throughout the full phase of heart development. We demonstrated
that homozygous knockout of Ezh2 in mouse hearts led to lethal
cardiovascular malformations with underdevelopment of the ECs.
Ezh2 mutant hearts also exhibited decreased cardiomyocyte
proliferation and increased apoptosis. We further showed that
Hey2, a member of the hairy and enhancer of split related family,
was a downstream target of Ezh2, and this regulation was
independent of Notch signaling activity. These observations and
associated mechanisms we describe here provided novel insights
into the regulation of cardiac development by the epigenetic
modifier Ezh2.
Materials and Methods
Ethics Statement
The animals were handled in accordance with institutional
guidelines with the approval (protocol ID 11006) of the
Institutional Animal Care and Use Committee of the Texas
A&M University Health Science Center at Houston.
Generation of genetically modified mice
The generation and characterization of Ezh2 floxed (Ezh2
fl/fl)
mice, in which the SET domain that harbors enzymatic activity
was flanked by loxP sites, were detailed previously [23]. Ezh2
fl/fl
mice were crossed with Nkx2.5-cre mice [27] to eventually produce
conditional Ezh2 mutant Ezh2
fl/fl:Nkx2.5-cre+ (Ezh2-cKO) mice.
Timed matings between Ezh2
fl/+:Nkx2.5-cre+ and Ezh2
fl/fl mice
were arranged as needed, and the day when a plug was seen was
taken as E0.5. Embryos or embryonic hearts at various
developmental stages such as E10.5, E12.5, E16.5, E18.5 or
postnatal day (P) 1 were collected for RNA/protein analysis, or for
histology. All animal procedures were performed in compliance
with institutional guidelines and with approved protocol ID 11006
of the IACUC at the Texas A&M University Health Science
Center at Houston.
Antibodies
Antibodies against trimethyl-histone 3-Lys27 (H3K27Me3),
Tbx2 and Sox9 were purchased from Millipore. Antibodies
against Ki67 and Snail were obtained from Abcam. Monoclonal
anti-cardiac Troponin T (cTnT) antibody was from Lab Vision.
Anti-phospho Histone 3-Ser10 (pH 3) was purchased from
Upstate, monoclonal anti-alpha-smooth muscle actin (a-SMA)
from Sigma, and anti-PECAM1 antibody from BD Biosciences.
Antibodies against Ezh2, NFATc1, Histone H3 (H3) and GAPDH
were from Santa Cruz Biotechnology, Inc. The fluorophore-
conjugated secondary antibodies Alexa FluorH 488 (donkey anti-
mouse) and 594 (goat anti-rabbit) were from Invitrogen.
Plasmid construction, cell culture, transient transfection
and western blot
Mouse Ezh2 cDNA was PCR-amplified and inserted in frame
after the HA tag of the PCGN vector via KpnI and BamHI sites
(PCGN-Ezh2). The Notch reporter pJT123A, which contains 86
CBF binding sites [28], and the cDNA of the intracellular domain
of Notch 2 (Notch2-ic) were gifts from Dr. Paul Ling (Baylor
College of Medicine, Houston, USA). The Notch2-ic cDNA was
then subcloned into PCGN vector after the HA tag on KpnI and
BamHI sites (PCGN-hNotch2-ic). The cDNA inserts of Ezh2 and
hNotch2-ic were confirmed by sequencing. The Hey2 promoter
luciferase reporter construct (Hey2-Luc), which contains a 1 kb
fragment of the Hey2 promoter region, was a gift from Dr.
Kimberly Foreman (Loyola University Medical Center, Maywood,
USA [29]). HeLa cells were maintained in Dulbecco’s Modified
Eagle’s Medium containing 10% fetal bovine serum. Transient
transfections were performed using HeLa cells cultured in 24 well
plates for using Lipofectamine 2000 (Invitrogen) according to the
protocol provided by the manufacturer. Luciferase activity assays
were then performed as detailed previously [30,31]. Briefly,
100 ng of Hey2-Luc or pJT123A was co-transfected with the empty
vector as a control or with various dosages of expression vectors, as
indicated in the figure legend. The empty vector was used to
maintain the balance of the total amount of plasmids used in the
reporter assay. Luciferase activity was measured 48 h after
transfection using Monolight
TM 3010 (Pharmingen). Promoter
activity was expressed as the ratio of luciferase activity obtained in
the presence of specific factor(s) to that of the control group with
the presence of only empty vector. Luciferase activity was
expressed as mean 6 SEM from at least two independent assays,
with each carried out in duplicate.
Western blots (WB) were performed on lysates purified from
E18.5 hearts. Protein extract (120 mg) from control and Ezh2-cKO
hearts was subjected to electrophoresis using 4–12% NuPage SDS
gel (Invitrogen) and then transferred to PVDF membrane and WB
performed using the antibodies indicated in the figure legend, and
visualized with chemiluminescence.
Reverse transcription-PCR (RT-PCR) and microarray assays
RNAs were extracted from wild type (WT) embryonic hearts at
indicated developmental stages, or from E16.5 control (Ezh2
fl/fl)
and Ezh2-cKO hearts, using Trizol according to the manufacturer’s
protocol. Microarray service was provided by Phalanx Biotech
(OneArray Express) with three samples per group, and each
sample was analyzed in triplicate. Reverse transcription reaction
was carried out using 1 mg total RNA, cloned reverse transcriptase
(Invitrogen) and Oligo dT, which generated a final 50 ml volume
reaction to generate the complementary DNA (cDNA). The
cDNA (1 ml for Ezh2 and 0.5 ml for GAPDH, respectively) was
subsequently used in semi-quantitative PCR with two alternative
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(Applied Biosystems) using SYBRH-Green and the gene-specific
probes. The sequences of oligos used in this study are shown
below: Ezh2: forward, 59 ACTTACTGCTGGCACCGTCT 39,
reverse, 59 TGCATCCACCACAAAATCAT 39; Ezh1: forward,
59 TGGTGTCTTGCAAAAACTGC 39, reverse, 59 AGGTTG-
AAGAGGAAGCTGGA 39; Hey2: forward, 59 AAGCGCC-
CTTGTGAGGAAAC 39, reverse, 59 CCCTCTCCTTTTCTT-
TCTTGC 39; GAPDH: forward, 59 ATGTTCCAGTATGACTC-
CACTCAC 39, reverse, 59 GAAGACACCAGTAGACTCCAC-
GA 39.
Histology, alcian blue staining and immunofluorescence
staining
For histological analysis, embryos or heart tissues were fixed in
10% paraformaldehyde (PFA) at the stages indicated in each
figure legend, dehydrated and embedded in paraffin for
preparation of histological sections at 5 or 10 mm thickness.
The slides were rehydrated, followed by hematoxylin and eosin
(H&E) staining according to the manufacturer’s instructions.
Alcian blue staining was performed according to the manufac-
turer’s instructions.
The procedure of immunofluorescence staining was described
previously [32]. Briefly, for antigen retrieval, the sections were
boiled in sodium citrate buffer (10 mM, pH=6.0), and subse-
quently blocked in 2% normal goat serum/PBST (16PBS/0.05%
Tween20), incubated with the primary antibody of interest at
appropriate concentration, followed by fluorophore-conjugated
secondary antibodies in blocking solution. TUNEL staining was
conducted with ApopTagH Red In Situ Apoptosis Detection Kit
according to the manufacturer’s protocol (Millipore). Sections
were mounted with Vectashield with DAPI (Vector Laboratory)
and photographed under an Olympus fluorescence microscope.
The number of phospho Histone H3 (pH 3) positive, Ki67 positive
or TUNEL positive cells (pH 3
+, Ki67
+ or TUNEL
+) was scored
in at least three randomly selected fields in the left ventricle or
atrioventricular cushion of E12.5 or in the atrioventricular septum
of E16.5 hearts, and expressed as mean 6 SEM. The number of
double Tbx2 and alpha-SMA positive cells (Tbx2
+:alpha-SMA
+)
was scored in at least three randomly selected fields in the
atrioventricular cushion region of E12.5 hearts. The number of
Sox9 positive cells (Sox9
+), or Snai1 positive cells (Snai1
+) was
scored in the atrioventricular cushion region of E12.5 hearts. The
data were expressed as mean 6 SEM.
Chromatin immunoprecipitation assay (ChIP)
ChIP assay was performed using the EZ-ChIP
TM chromatin
immunoprecipitation kit (Millipore, USA) according to manufac-
turer’s instructions, with slight modification. Briefly, homogenized
heart tissues were crosslinked with 1% formaldehyde for 20 min at
room temperature, harvested, and rinsed with 16PBS. Cell nuclei
were then isolated, pelleted, and sonicated. DNA fragments were
subsequently enriched by immunoprecipitation with anti-Ezh2
antibody or with IgG as a control. The precipitated genomic DNA
was washed, eluted from the antibody or IgG, and crosslinks were
reversed by heating at 65uC. Thereafter, the DNA was recovered
by phenol/chloroform extraction followed by ethanol precipitation
and washing. The purified DNA pellet was resuspended in 16TE
buffer for subsequent PCR assay using the following primers
targeting the first half of CpG island upstream of the transcrip-
tional initiation site (TIS) of the Hey2 gene: forward, 59
CACGCGCTAGCGGTTATTCT 39; reverse, 59 CACGCTG-
CAGCCCAGCCAG 39.
Statistical analysis
The unpaired Student’s t test or Chi-square test was applied to
determine statistical significance between groups when applicable
and the respective p-value is shown in each figure legend. p,0.05
was defined as significant and p,0.01 as highly significant.
Results
Conditional deletion of Ezh2 in murine hearts led to
CHDs
To explore the function of Ezh2 in cardiogenesis, we first asked
if Ezh2 was expressed in the developing mouse heart. Semi-
quantitative RT-PCR with two different PCR cycle numbers (30
and 35) was performed on RNA samples purified from E9.5,
E10.5 and E11.5 WT embryonic hearts using a pair of oligos
against the SET domain of Ezh2 (Fig. 1A, upper panel). Ezh2
mRNA was detected as early as E9.5 (Fig. 1B), consistent with the
previous report [24]. Next, Ezh2
fl/fl mice were crossed with Ezh2
fl/+:
Nkx2.5-cre+ mice to generate cardiac-specific Ezh2 knockout (Ezh2-
cKO) mice. To assess the deletion efficiency of Ezh2 in heart, qRT-
PCR was performed on cDNAs obtained from RNAs of E16.5
Ezh2
fl/fl (control) and mutant Ezh2-cKO hearts using the primers
mentioned above. A pair of oligos against the SET domain of Ezh1
(Fig. 1A, lower panel), the other Ezh family member, was used as a
control. The mRNA expression of Ezh2 in the Ezh2 null hearts was
decreased by ,70% relative to the control, and as expected, the
expression of Ezh1 was not affected (Fig. 1C). Correspondingly,
Western blot analysis of E18.5 heart lysates prepared from control
and Ezh2 mutant mice showed a significant reduction in
H3K27Me3 in Ezh2-cKO heart (Fig. 1D, upper panel), even in the
presenceofaslightlyincreasedlevelofthetotalHistoneH3(Fig.1D,
middle panel), while no significant difference in the GAPDH level
between these two groups was observed. These results indicate
reduced Ezh2 function in the Ezh2 mutant heart.
While Ezh2
fl/+:Nkx2.5-cre+ mice appeared normal, viable and
fertile, all Ezh2
fl/fl: Nkx2.5-cre+ newborn pups died before P3
(mortality rate 100%, compared with 12.50% of Ezh2
fl/+, 6.90%
of Ezh2
fl/+:Nkx2.5-cre+, and 10% of Ezh2
fl/fl, respectively, Fig. 1E),
with a slight deviation of P1 frequency (20.20%) from the
expected Mendelian rate of 25% (Fig. 1F). Timed matings
recovered mutant embryos at a low frequency (16%) at
embryonic stages between E16.5 and E17.5 (Fig. 1G), indicating
embryonic loss at later gestational stages. As shown in Fig. 1H,
we indeed found dead Ezh2-cKO embryos at E16.5. To
understand the cause of death of Ezh2 mutant mice, histological
examination was performed on control (n=11) and mutant
(n=10) hearts, and revealed 100% penetrance of cardiac defects
for mutant mice, and only ,9.1% for control (Fig. 2K,
p,0.0001). A variety of cardiovascular structural malformations
was observed in the mutant mice, including double outlet right
ventricle (DORV, 30%, Fig. 2E), in which the aorta was
connected to the right ventricle instead of the left ventricle;
persistent truncus arteriosus (PTA, 20%, Fig. 2, see the transition
of PTA from F to G), in which a defective septation between the
pulmonary trunk and the aorta allowed a communication
between these two great vessels; membranous ventricular septal
defects (VSDs, 60%, Fig. 2E, F, G & J); muscular VSDs (80%,
Fig. 2H); atrial septal defects (ASDs, 60%, Fig. 2I); atrioventric-
ular canal defects (AVCD, 20%, Fig. 2J). In addition, 3 out of 10
mutant mice examined exhibited enlarged aortic valves (Fig. 2,
compare F9 or G9 with B9). There was no discernible structural
phenotype(s) in the ventral pharyngeal endoderm of Ezh2 mutant
hearts at E10.5 (data not shown), where Nkx2.5-cre is also active.
Ezh2 and Congenital Heart Defects
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31005Figure 1. Conditional knockout of Ezh2 gene in murine hearts caused perinatal lethality. (A) Schematic illustration showing the annealing
sites of primer pairs of mouse Ezh2 and Ezh1 (a homolog of Ezh2). (B) Ezh2 expression in the murine embryonic hearts. Semi-quantitative RT-PCR with
two different numbers of amplification cycles (30 and 35) was performed on RNA samples purified from WT hearts of E9.5, E10.5, and E11.5. 1 mlo r
0.5 ml cDNA from reverse transcription reaction was used for detection of Ezh2 or GAPDH (as a control), respectively. (C) qRT-PCR analysis revealed
,70% decrease in Ezh2 mRNA of Ezh2-cKO heart (n=3, p,0.001), but Ezh1 mRNA was not affected, compared with that of the control littermate
hearts. Data are presented as mean 6 SD of 3 replicate samples for each strain/gene analyzed. (D) The level of H3K27Me3 was reduced in the E18.5
Ezh2-cKO hearts, compared to that of control. The total Histone H3 and GAPDH both serve as controls. The asterisks indicate H3K27Me3. NS, non-
specific. (E) The neonatal mortality rate (%) and (F) the P1 frequency of four different genotypes resulting from the crossbreeding between Ezh2
fl/+:
Nkx2.5-cre+ and Ezh2
fl/fl mice. Data in panel E & F represent the average of 12 litters comprising a total of 99 animals. (G) The number and recovery
rate (in parenthesis) of Ezh2
fl/+, Ezh2
fl/+:Nkx2.5-cre+, Ezh2
fl/fl, and Ezh2
fl/fl:Nkx2.5-cre+ embryos collected at various embryonic stages are shown.
Offspring from intercrossing between genotypes of Ezh2
fl/fl and Ezh2
fl/+:Nkx2.5-cre+ mice. Note that the expected Mendelian rate of embryo recovery
for each of these four genotypes is 25%. (H) Embryonic demise of Ezh2 mutant mice at a later gestational stage. The representative images of E16.5
WT and dead Ezh2 mutant embryos are shown.
doi:10.1371/journal.pone.0031005.g001
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in normal cardiovascular morphogenesis.
Impaired endocardial cushion development in Ezh2
mutant hearts
Normal development of the ECs is essential for the formation
of outflow tract and proper septation of atria and ventricles. The
presence of DORV, perimembranous VSD and AVCD in Ezh2
mutant mice prompted us to ask whether Ezh2 regulated EC
development. Since EC region in the AV canal started to develop
at ,E9.5, we first performed H&E staining on E10.5 heart
sections prepared from control and Ezh2 mutant embryos (n=3/
group) to investigate EC formation. Although the morphology of
ECs in the mutant heart appeared indistinguishable from that in
the control heart at this stage, it displayed substantially fewer cells
in the cardiac cushions (Fig. 3A & B, arrows), indicating impaired
EC development. The reduction in cell population in the EC
region could be attributed to either decreased cell proliferation,
or increased cell apoptosis, or both. To investigate which
mechanism(s) underlied defective EC development, staining of
Ki67, a cell proliferation marker, was first performed on E10.5
heart sections of both control and mutants. A considerable
reduction in the cell proliferation in the EC region of Ezh2
mutant hearts (,40/field) compared with control hearts (,68/
field, p,0.05) was observed (Fig. 3C,D9 & G). At E10.5, the
trabeculae of the Ezh2 mutant hearts were not well formed
(Fig. 3A9 &B 9, arrowheads). The compact zone of mutant hearts
was not significantly thinner compared with that of WT hearts at
this stage; however, a significant decrease in cardiomyocyte
proliferation in the compact zone of mutant hearts was already
seen (Fig. 3C0 &D 0, and see below). TUNEL staining performed
on the same heart samples mentioned above revealed a
significant elevation in apoptosis in the mutant hearts (Fig. 3E–
F9 & H, n=3/group, p,0.05). Thus, deletion of Ezh2 was
responsible for both decreased cell division and increased
apoptosis in the EC region, consequently leading to hypoplastic
ECs.
Endothelial-to-mesenchymal transition (EMT) was
impaired in Ezh2 mutant hearts
Endocardial cushions (ECs) are believed to originate from two
major cell types: cardiac neural crest cells, which participate in the
formation of the distal part of cardiac outflow tract, and
endothelial cells, which undergo EMT and comprise ECs in the
AV canal. EMT is a critical process in the EC development, and
defective EMT can lead to a number of cardiac malformations
such as AVCD, DORV and membranous VSD, as observed in the
Ezh2 mutant mice. To explore whether EMT was negatively
affected in the Ezh2 mutant hearts, we stained tissues for the
endothelial cell marker PECAM1 and transformed mesenchymal
cell marker a-SMA to detect endothelial cells or transformed
mesenchymal cells in the AV canal. At E10.5, PECAM1
+
endothelial cells lined the ECs as previously observed [33], and
no significant change in the PECAM1
+ cells between control and
Ezh2 mutant hearts was observed (Fig. 4A & B). At this stage, a-
SMA+ cells were barely detected in either group. At E12.5, the
pattern of PECAM1 staining in the EC region was similar to that
at E10.5, but the a-SMA
+ cells could be detected in both groups.
However, the number of a-SMA
+ cells—cushion mesenchymal
cells undergoing SM differentiation—in the Ezh2 mutant hearts
Figure 2. Characterization of cardiac phenotypes in Ezh2-cKO mice. (A–D) H&E staining of the coronal sections of the control mouse hearts at
P1 showed normal structure of heart and great vessels. (E–J) H&E staining of the coronal sections of the Ezh2-cKO (Ezh2
fl/fl:Nkx2.5-cre+) hearts at P1
showed a variety of cardiovascular defects: E, double outlet right ventricle (DORV) and perimembranous ventricular septal defect (VSD, arrow); F & G,
two serial sections showing the transition of persistent truncus arteriosus (PTA). F9 and G9 are the amplification of the boxed region in F and G,
respectively. Arrows in G and G9 indicate the septal opening; H, muscular VSD (arrow); I, atrial septal defect (ASD, arrow); J, atrioventricular canal
defects (AVCD, upper arrow) and membranous VSD (lower arrow). (K) The penetrance of cardiac defects in the mutant hearts was 100%, with variable
incidence of different CHDs, as indicated. RV: right ventricle; LV, left ventricle; RA, right atrium; LA, left atrium; Ao, Aorta; PT, pulmonary trunk. n=10.
Scale bar: 100 mm.
doi:10.1371/journal.pone.0031005.g002
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E, F, arrows), indicating defects in mesenchymal cell differentia-
tion. To further examine the defect of EMT in the Ezh2 mutant
heart, we stained for Sox9 and Snai1, both of which are
transcription factors important for the EMT process [33,34].
The number of either the Sox9
+ (Fig. 4G, H9 & K) or the Snai1
+
cells (Fig. 4I,J9 & L) in the ECs of Ezh2 mutant hearts was
significantly reduced by ,30% compared with those in littermate
control hearts (p,0.05, n=3/group), further supporting that
EMT was impaired.
Normal EC development requires invasion of endocardial-
derived mesenchymal cells into the cardiac jelly within the AV
canal, and impairments in formation of the cardiac jelly could also
lead to deficient EMT. To address this issue, alcian blue staining,
which can visualize acid glycosaminoglycans, such as hyaluronic
acid within and surrounding the ECs, was performed on sections
of embryonic hearts prepared from E10.5 Ezh2
fl/fl and Ezh2-cKO
embryos. Both control and Ezh2 mutant hearts exhibited
comparable pattern of staining (Fig. 4M & N). Thus, the cardiac
jelly formation did not account for the deficient EMT seen in the
Ezh2 mutant hearts.
Tbx2 was downregulated in the AV myocardium of Ezh2
mutant hearts
Since the cardiac phenotypes observed in the Ezh2-cKO mutant
mice such as defective EC formation and OFT septation were
similar to those observed in mice homozygous for Tbx2 and
NFACTc1, both of which were shown to be important for
specification and differentiation of endocardial cushion
[35,36,37], we first examined the expression of NFATc1 in the
AV canal in both control and Ezh2-cKO hearts at E10.5. The
staining of NFATc1 showed no significant difference between
these two groups (Fig. 5A & B). We next examined Tbx2
expression in these hearts at two developmental stages, E10.5
and E12.5, respectively. The expression of Tbx2, which was mainly
localized in the AV myocardium of the EC region, was
significantly decreased by ,50% in the Ezh2 mutant hearts
compared with that in the control hearts at both embryonic stages
examined (Fig. 5 C, D, E, F, G, arrows. n=3/group, p,0.05).
Thus, the reduction in Tbx2 expression in the Ezh2-cKO heart
could be a contributing factor in the development of deficient ECs,
and subsequently, of cardiovascular malformation.
Figure 3. Ezh2
fl/fl:Nkx2.5-cre+ mice exhibited hypoplastic endocardial cushions. (A–B9) H&E staining revealed a decrease in the cell
population in the EC region of Ezh2 null hearts compared with that of control (arrows) at E10.5. Also, Ezh2 mutant heart displayed defective
trabeculation (arrowheads). A9 and B9 are the amplification of the boxed region of A and B, respectively. A&B ,2 0 6magnification; A9 &B 9,4 0 6
magnification. (C–D0 &G ) Double-immunofluorescence with anti-Ki67 antibody (red) and anti-cardiac Troponin T antibody (cTnT, green) revealed a
reduced number of Ki67
+ cells in both the compact myocardium and the AV cushion of Ezh2-cKO hearts at E10.5, compared with that of littermate
controls. C9 and D9 are the amplification of the bigger boxed region of C and D; C0 and D0 are the amplification of the smaller boxed region of C and
D. C&D ,2 0 6magnification; C9–D0,4 0 6magnification. Scale bar, 100 mm. G shows that the number of Ki67
+ cells was significantly decreased in
Ezh2-cKO hearts relative to the control. The number of Ki67
+ cells was counted from 10 randomly selected fields in the ECs. Data are presented as
mean 6 SD. *, p,0.05. n=3 per group. (E–F9 &H ) Double immunofluorescence of TUNEL staining (red) and anti-cTnT (green) revealed an increased
number of TUNEL
+ cells in both the AV cushion of Ezh2-cKO hearts at E10.5, compared with that of littermate controls. Nuclei were counterstained
with DAPI, as shown in blue. E9 and F9 are the amplification of the boxed region of E and F respectively. E&F ,2 0 6magnification; E9&F 9,4 0 6
magnification. Scale bar: 100 mm. H shows that the number of TUNEL
+ cells was significantly increased in Ezh2-cKO hearts relative to the control. The
number of TUNEL
+ cells was counted from 10 randomly selected fields. Data are presented as mean 6 SD. *, p,0.05. n=3 per group. OFT, outflow
tract; A, common atrium; V, common ventricle.
doi:10.1371/journal.pone.0031005.g003
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apoptosis in the compact and trabecular myocardium of
Ezh2 null hearts
Given the observed decreased cardiomyocyte proliferation in
the compact zone of Ezh2-cKO hearts at E10.5 (Fig. 3C0&D0), we
further characterized the molecular phenotypes in the myocardi-
um of Ezh2 mutant hearts compared with that of littermate
controls at a later stage, E16.5. In the mutant hearts, the
trabeculae were not well defined (Fig. 6A & B, arrows), and the
compact zone of the ventricular wall was thinner (Fig. 6A & B,
bars), indicating defective myocardial maturation. Next, cardio-
myocyte proliferation was examined by pH 3 staining. The
number of cardiomyocytes entering the mitotic phase was
significantly higher in control hearts (Fig. 6C & D, ,16/field,
n=3) than in Ezh2 mutant hearts (,5/field, n=3, p,0.05,
Fig. 6I). Consistent with this observation, the number of total
dividing cardiomyocytes was reduced in mutant hearts (Fig. 6E &
F, arrows, ,62/field, n=3) compared with that in control hearts
(,98/field, n=3, p,0.05, Fig. 6J). These observations further
indicated that Ezh2 is an important regulator of cardiomyocyte
division, in line with the reports of involvement of Ezh2 in
regulating the cell cycle in other tissues/cell lines [13,17]. We also
examined apoptosis in Ezh2 mutant and control hearts at this stage
using TUNEL assay, and observed a significant difference in the
number of apoptotic cardiomyocytes between these two groups
(Fig. 6G, H & K, arrows; mutant ,2.5/field vs. control 0.5/field,
Figure 4. Ezh2
fl/fl:Nkx2.5-cre+ mice exhibited impaired endothelial-to-mesenchymal transition (EMT) in the AV cushion. (A–F) Double-
immunofluorescence staining of the sagittal sections of E10.5–12.5 embryos with anti-PECAM1 antibody (red) and anti-a-SMA (green) revealed a
reduced number of a-SMA
+ cushion mesenchymal cells (arrows) in Ezh2
fl/fl:Nkx2.5-cre+ hearts compared with that of control hearts. At E10.5 and
E12.5, PECAM1
+ cells were detected lining the AV cushion, and no difference of PECAM1
+ cells was observed between Ezh2 mutant and control (A–
D9). a-SMA
+ cells were barely visible in the EC region at E10.5 in both control and mutant hearts (A&B ), but were detected at E12.5 (C&D 9, boxed
areas). However, the number of a-SMA
+ cells in the control EC region was significantly higher than that in the Ezh2 mutant heart (C9 &D 9, arrows). C9
and D9 are the amplification of the boxed area of C and D, respectively. Note that the cluster of a-SMA
+ cells observed in D9 was the migrating
myocardium; only the isolated independent a-SMA
+ cells (arrows) were EMT cells. Two additional independent sections also showed more a-SMA
+
cells in control (E, arrows) than in Ezh2
fl/fl:Nkx2.5-cre+ (F). A–D,2 0 6magnification; C9,D 9,E ,F ,4 0 6magnification. Scale bar: 100 mm. (G–L) Double
immunofluorescence staining of the sagittal sections of E12.5 embryos with anti-Sox9 antibody (red, G–H9) or anti-Snai1 antibody (red, I–J9) and anti-
alpha-SMA (green) revealed reduced number of Sox9
+ and Snail
+ cells in the atrioventricular endocardial cushion of Ezh2-cKO hearts compared with
that in the littermate control hearts (n=3). K and L show the statistical analysis of the number of Sox9
+ and Snail
+ cells, respectively, in the
atrioventricular endocardial cushion per histological section between these two groups. Data are presented as mean 6 SD. n=3 for each group.
*, p,0.05. Magnification, 206for G, H, I and J, and 406for G9,H 9,I 9 and J9. Scale bar: 100 mm. (M–N) Alcian blue staining in the EC extracellular
matrix of E10.5 hearts showed no significant difference in morphology between Ezh2 mutant and control hearts (n=3/group). Magnification, 106.
Scale bar: 100 mm.
doi:10.1371/journal.pone.0031005.g004
Figure 5. Decreased Tbx2 expression in the AV myocardium of Ezh2 mutant mice. (A–B) Double immunofluorescence staining of the
sagittal sections of E10.5 embryos with anti-NFATc1 antibody (red) and anti-alpha-SMA (green) revealed no change in the number of NFATc1
+
endothelial cells in Ezh2-cKO hearts compared with that in littermate control hearts. (C–F) Double-immunofluorescence staining of the sagittal
sections of E10.5–12.5 embryos with anti-Tbx2 antibody (red) and anti-alpha-SMA (green) revealed greatly reduced Tbx2
+:a-SMA
+ (arrows) primary
myocardial cells of the atrioventricular canal in Ezh2
fl/fl:Nkx2.5-cre+ hearts, compared with that of the littermate control hearts. Dotted lines outlined
the valve primordia. The number of Tbx2
+:a-SMA
+ cells was counted in three randomly selected fields of Ezh2
fl/fl:Nkx2.5-cre+ and control hearts of
E10.5 or E12.5 embryos. Nuclei were counterstained with DAPI, as shown in blue. G shows the statistical analysis of Tbx2
+:a-SMA
+ cells between these
two groups. Data are presented as mean 6 SD. n=3 for each group. *, p,0.05. Magnification, 206. Scale bar: 100 mm.
doi:10.1371/journal.pone.0031005.g005
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Ezh2’s essential role in cardiomyocyte proliferation and survival.
Ezh2 regulated the expression of Hey2 gene
To further identify potential Ezh2-dependent genetic pathways
that regulate cardiac development, we generated gene profiling
data from E16.5 RNA from control and Ezh2-cKO heart s (n=3/
group) to look for up- or down-regulation of candidate factors
critical for cardiac morphogenesis, including the EC development.
In the Ezh2 mutant hearts, there was no significant decrease in the
transcription level of a number of factors that have been shown to
be critical for heart development, i.e., as Foxp1, Tgfb2, BMP2/
BMP4, Tbx1, Tbx5, Foxm1, GATA4, 5, 6 (Table 1). However, Hey2,
a basic helix-loop-helix (bHLH)-containing transcription factor
that is required for AV canal development [38], was significantly
decreased by ,40% (p=0.022, data not shown); the decrease in
expression of Hey2 in the Ezh2 mutant hearts was further
confirmed by quantitative RT-PCR (Fig. 7A, n=3/group,
p=0.006). The Hey2 mRNA level was also significantly reduced
in the Ezh2
2/2 embryoid bodies (data not shown). The Ezh2-
mediated Hey2 expression appeared to be specific because Hey1
and Heyl, the other two members of Hey family, and all other hes
transcripts were expressed normally (Table 1). Hey2 and other Hey
family members were identified as Notch signaling targets
[39,40,41]; however, in the Ezh2 mutant hearts, the major
components of Notch signaling pathway displayed no significant
decrease in the transcription level (Table 1). Instead, Notch4 was
even significantly upregulated (Table 1). These data suggest Notch
pathway-independent regulation of Hey2 by Ezh2.
To probe if Ezh2 could directly regulate Hey2 expression, we
revealed the presence of a CpG island in the 59 flanking sequence of
Hey2 gene using a bioinformatics tool (EMBL-EBI). This CpG
island is 932 bp, and spans exon 1 of the Hey2 gene (Fig. 7B, upper
panel, smaller box), thus rendering Hey2 as a potential target for
Ezh2. To investigate if Ezh2 could directly bind to this CpG island,
ChIP assays were performed on WT hearts using anti-Ezh2
antibody, or as a control, IgG for pulldown; PCR was then
performed using the precipitated genomic DNA (gDNA) in
combination with primers designed to bind in the region flanking
the first half of the CpG island, which is immediately upstream of
the TIS of Hey2 gene (Fig. 7B, upper panel, arrows). Robust
binding of Ezh2 on the targeted region of CpG island was
observed, but not for the control (IgG-precipitated) gDNA (Fig. 7B,
lower panel). To explore if Ezh2 had any impact on the activity of
the Hey2 promoter, transactivation assays were carried out on
HeLa cells transfected with the Hey2-Luc reporter construct, which
Figure 6. Ezh2
fl/fl:Nkx2.5-cre+ mice exhibited defective formation of myocardial compact zone and trabeculation. (A–D & I) Double
immunofluorescence staining of the coronal sections of E16.5 hearts with anti-pH 3 antibody (red) and anti-cTnT antibody (green) revealed a reduced
number of double pH 3
+:cTnT
+ cells (arrows) in Ezh2
fl/fl:Nkx2.5-cre+ embryos. (A&B ) The left ventricular free wall (bar) was thinner and trabeculation
(arrows) was not well formed in E16.5 Ezh2
fl/fl:Nkx2.5-cre+ hearts, compared with that of the littermate controls. C&Dshow A&B(206) at a higher
magnification (406). I, the number of double pH 3
+:cTnT
+ cells was counted from at least three randomly selected fields of each sample and was
significantly reduced in E16.5 Ezh2
fl/fl:Nkx2.5-cre+ hearts. n=3/group. *, p,0.05. (E, F & J) Double-immunofluorescence staining of the coronal
sections of E16.5 hearts with anti-Ki67 antibody (red) and anti-cTnT antibody (green) revealed a reduced number of double Ki67
+:cTnT
+ cells (arrows)
in Ezh2
fl/fl:Nkx2.5-cre+ hearts relative to the littermate controls. Magnification, 206. J, the number of Ki67
+: cTnT
+ cells were counted from at least
three randomly selected fields of each sample and was significantly reduced in E16.5 Ezh2
fl/fl:Nkx2.5-cre+ hearts. n=3/group. *, p,0.05. (G, H & K)
Double-immunofluorescence analysis of TUNEL (red) and anti-cTnT antibody (green) stained coronal sections of E16.5 hearts revealed an increase in
the number of double TUNEL
+:cTnT
+ cells (arrows) in Ezh2
fl/fl:Nkx2.5-cre+ hearts. Magnification, 206. K, the number of TUNEL
+:cTnT
+ cells were
counted from at least three randomly selected fields and showed significantly increased in E16.5 Ezh2
fl/fl:Nkx2.5-cre+ hearts. n=3/group. *, p,0.05).
Nuclei were counterstained with DAPI and shown in blue. All data were presented as means 6 SD. Scale bar: 100 mm.
doi:10.1371/journal.pone.0031005.g006
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empty vector or increasing dosages of Ezh2. As shown in Fig. 7C,
Ezh2 potentiated Hey2-Luc activity up to ,28 fold in a dose-
dependent fashion.
The Notch pathway is also known to positively regulate Hey2
expression. To elucidate if there was any functional interaction
between Ezh2 and Notch signaling, various dosages of the vector
encoding the active domain of Notch2 (Notch2-ic) was transfected
into HeLa cells with or without Ezh2. Notch2-ic activated Hey2
promoter to a much less degree (up to ,3 fold, Fig. 7D, upper
panel) than Ezh2, and a slight synergy between Notch2-ic and Ezh2
was observed. We also tested the potential crosstalk between Ezh2
and Notch using the Notch reporter pJT123A, which contains only
CBF binding sites. As expected, Notch2-ic substantially increased
the activity of the Notch reporter up to ,158 fold (Fig. 7D, lower
panel), and Ezh2, at the tested dosage (0.5 mg), also activated this
Notch reporter to a comparable level as Hey2-Luc. Unexpectedly,
Ezh2 and Notch2-ic exerted a substantial synergistic effect on the
pJT123A reporter (up to ,229 fold at the two lowest doses of Ezh2
and Notch2-ic tested). Collectively, these findings demonstrate that
there is a functional interaction between Ezh2 and the Notch
pathway, particularly on the tested Notch reporter.
Discussion
As a chromatin remodeling enzyme, Ezh2 is involved in a
variety of cellular events and in development of certain tissues/
organs and functions by regulating target gene expression. Here
we reported a particular contribution of Ezh2 to normal
cardiovascular development using the approach of cardiac-specific
cre-mediated ablation of Ezh2 in murine hearts.
Our data revealed that Ezh2 is critical for the atrial and
ventricular septation process and for normal formation of OFT, as
demonstrated by a wide spectrum of cardiovascular anomalies
observed in the Ezh2 deficient hearts. The existence of structural
malformations such as AVCD, and perimembranous VSD in the
Ezh2
fl/fl:Nkx2.5-cre+ mice suggested defects in the EC formation,
while the muscular VSD possibly resulted from decreased
cardiomyocyte proliferation and/or increased apoptosis. Indeed,
Ezh2
fl/fl:Nkx2.5-cre+ mice exhibited hypoplastic ECs with normal
development of extracellular matrix. The decrease in Sox9
+ and
Snai1
+ cells, combined with the reduction of SMA
+ cells in the EC
region of Ezh2 mutant hearts, suggested that the transition from
the endothelial phenotype to mesenchymal phenotype was not
completed in the absence of Ezh2, and/or that the initiation of
Table 1. No significant decrease in the expression of Notch signaling molecules and major factors that are important for cardiac
development between control and Ezh2 mutant hearts.
RefSeq Description Gene_symbol fold changes P value
NM_053202.2 forkhead box P1 Foxp1 0.959558 0.695135
NM_009367.3 transforming growth factor, beta 2 Tgfb2 1.082478 0.443397
NM_007553.2 bone morphogenetic protein 2 Bmp2 0.876828 0.463695
NM_007554.2 bone morphogenetic protein 4 Bmp4 1.335088 0.019113
NM_011532.1 T-box 1 Tbx1 0.995352 0.989775
NM_008021.4 forkhead box M1 Foxm1 0.840488 0.267564
NM_008092.3 GATA binding protein 4 Gata4 1.009269 0.920405
NM_008093.2 GATA binding protein 5 Gata5 1.158629 0.171979
NM_010258.3 GATA binding protein 6 Gata6 0.94492 0.660179
NM_011537.3 T-box 5 Tbx5 1.255253 0.353991
NM_010929.2 Notch gene homolog 4 (Drosophila) Notch4 1.376186 0.007133
NM_010928.2 Notch gene homolog 2 (Drosophila) Notch2 1.090368 0.865985
NM_008716.2 Notch gene homolog 3 (Drosophila) Notch3 1.222591 0.208996
NM_008714.3 Notch gene homolog 1 (Drosophila) Notch1 0.98534 0.922807
NM_001080928.1,
NM_001080927.1,NM_009035.4
recombination signal binding protein
for immunoglobulin kappa J region
Rbpj 0.929803 0.482391
NM_019454.3 delta-like 4 (Drosophila) Dll4 1.254778 0.450871
NM_013822.4 jagged 1 Jag1 1.214836 0.495276
NM_010423.2 hairy/enhancer-of-split related with YRPW motif 1 Hey1 1.192812 0.38495
NM_013905.3 hairy/enhancer-of-split related with YRPW motif-like Heyl 1.165378 0.431993
NM_008235.2 hairy and enhancer of split 1 (Drosophila) Hes1 0.984655 0.941856
NM_010419.4 hairy and enhancer of split 5 (Drosophila) Hes5 1.054865 0.517022
NM_019479.3 hairy and enhancer of split 6 (Drosophila) Hes6 1.048307 0.713259
NM_008236.4 hairy and enhancer of split 2 (Drosophila) Hes2 1.119306 0.789934
NM_008237.4 hairy and enhancer of split 3 (Drosophila) Hes3 1.031301 0.766008
NM_033041.4 hairy and enhancer of split 7 (Drosophila) Hes7 1.03991 0.775866
NM_008004.4 fibroblast growth factor 17 Fgf17 1.11111 0.653293
Microarray (OneArray Express) was performed on RNAs extracted from E16.5 control (Ezh2
fl/fl)a n dEzh2-cKO hearts. n=3/group, with each sample carried out in
triplicate.
doi:10.1371/journal.pone.0031005.t001
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sion, given the critical role Snai1 plays in activating EMT [33].
However, the deficient EC development of Ezh2 null hearts should
be a consequence of the combined effects of decreased cell
proliferation, increased apoptosis and impaired EMT, although
the individual role that each of these three aspects plays in the
defective EC formation remains to be dissected. It has to be
pointed out that the Ezh2 deficiency-associated cell proliferation
defect and increased apoptosis observed in the EC region was not
specific for ECs. Instead, it was a part of a global effect; similar
alterations were also present in the other regions of the mutant
hearts, such as in the ventricular walls and septum. Therefore,
Ezh2 regulates cardiomyocyte proliferation and survival in
different regions of the developing heart and at different stages
of its development.
Although we did not investigate particularly whether the OFT
cushion that derived from cardiac neural crest cells was affected in
the Ezh2
fl/fl:Nkx2.5-cre+ mutant, the presence of DORV, PTA and
defective semilunar valve leaflets of OFT indicated defective
cardiac neural crest-derived mesenchyme, although these anom-
alies were not as prevalent as the other cardiac phenotypes. Our
results were in line with the observation that Nkx2.5
+ cardiac
progenitors contributed to the formation of both the AV and OFT
cushions [42]. Indeed, using Nkx2.5-cre to delete BMP4 also caused
defective OFT septation with impaired neural crest-derived
smooth muscle [43]. Our observations pointed to the possibility
that Ezh2 was present in the cardiac neural crest cells and was
required for outflow tract formation. To fully understand the
function of Ezh2 in the cardiac neural crest formation,
specification and/or migration, alternative strategies such as the
Wnt1-cre system, in which Cre recombinase expression is driven by
the Wnt1 promoter and enhancer and has often been used to
conditionally delete target gene(s) in the neural crest lineage
[44,45], should be employed.
We further examined two factors that are involved in the AV
canal development and outflow tract formation, Tbx2 and
NFATc1, by immunostaining. We showed no significant change
in NFATc1, a factor which is critical in promoting the loss of
Figure 7. Ezh2 regulated Hey2 expression. (A) RT-qPCR confirmed downregulation of Hey2 expression in the Ezh2 mutant hearts. n=3 per
group. Student’s t-test was used for statistical analysis. (B) Ezh2 directly bound to the CpG island upstream of the Hey2 gene. Upper panel: A putative
CpG island was located in its 59 cis-regulatory region (as indicated by the smaller square), spanning exon 1 of Hey2 gene. Arrows indicate the locations
of oligos for ChIP assay. Lower panel: PCR on ChIP DNA showed direct binding of Ezh2 to the CpG island. Pulldown with IgG served as a control. (C)
Ezh2 potentiated Hey2 promoter activity in a dose-dependent manner. (D) Functional interaction between Ezh2 and Notch in the activation of target
promoters. Transfection was performed using HeLa cells as described in Materials and Methods. The doses of plasmids used in the transactivation
assays are indicated. The data shown were obtained from at least two independent assays with each carried out in duplicate. The group with Ezh2 ‘‘0’’
and Notch2-ic ‘‘0’’ in D is the control. The number shown above each bar indicates the fold change of that particular group.
doi:10.1371/journal.pone.0031005.g007
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in the AV canal myocardium of the Ezh2-cKO. Given that the Tbx2
knockout embryos exhibited AV canal defects and outflow tract
misalignment [35], the reduction in Tbx2 expression in the AV
myocardium of Ezh2 null mice could be a factor that facilitated
development of the cardiac anomalies observed in Ezh2-cKO mice.
Intriguingly, a significant reduction in Tbx2 expression was only
observed in the AV canal myocardium, but not in the other areas
such as the ventricular wall and septum (data not shown). How
Ezh2 regulates Tbx2 expression specifically in the myocardium of
AV canal remains open for further investigation.
Notch signaling is important for normal cardiac development,
as evidenced by a number of studies in which mutation of Notch
signaling component(s) caused cardiac defects [46]. Activation of
Notch signaling elements such as Notch 4 promoted EMT [47]. In
our study, we noticed a significant upregulation of Notch4
transcription in the Ezh2 mutant hearts relative to the WT
controls. Despite this increase, however, EMT in the Ezh2-cKO
hearts was not enhanced but instead was underdeveloped; this
effect was opposite to the consequence of elevated Notch 4 activity.
Also, a number of proposed downstream targets in the Notch
signaling pathway that we examined were not significantly
increased either in the Ezh2 mutant hearts. These findings
collectively suggested that 1) the increase of Notch 4 was not
sufficient to significantly increase the expression of Notch target
genes in the absence of Ezh2, and 2) the heart defects observed in
the mutant Ezh2
fl/fl:Nkx2.5-cre+ mice was not due to the increased
Notch signaling activity.
In the current study we identified Hey2 as a downstream target
of Ezh2. Hey2 was highly expressed in the embryonic cardiovas-
cular system [48], and correspondingly, knockout of Hey2 in mice
caused cardiovascular anomalies (variable phenotypes, depending
upon the strain) and perinatal death; [49,50,51]. Hey2 was also
involved in regulating apoptosis [52]. The observations associated
with Hey2 knockout included thinner ventricular wall, defects of
cardiac septation and outflow tract formation, accompanied with
decreased proliferation, which were similar to the defects observed
in the Ezh2 deficient murine hearts. Hey2 was proposed to have an
important role in the formation of ECs [51]; however, its specific
function in the EC development, i.e., EMT, cell proliferation or
survival of EC region, remains to be determined. The significant
decrease in the expression level of Hey2 gene in the Ezh2 mutant
heart could be an important factor that contributed to the
development of cardiovascular malformations.
Although Hey2 was first identified together with other hairy-
related bHLH transcription factors as direct targets of the Notch
signaling pathway [41], a number of recent studies suggested that
Notch signaling was dispensable for the regulation of Hey2
expression in certain tissues/organs such as chick heart and the
caudal presomitic mesoderm [53,54]. A FGF signaling molecule,
FGF17, also regulated Hey2 gene expression in the pillar cells of
the organ of Corti independent of Notch signaling [55]. In the
Notch1 null ventricular myocardium, the Hey2 level was also not
significantly affected [56]. Our finding of downregulation of Hey2
expression in the Ezh2-deficient hearts suggested that Hey2 was a
downstream target of Ezh2 and that this regulation was
independent of both Notch signaling activity and FGF17 because
no significant decrease in the transcripts of Notch signaling
components or FGF17 was observed in the Ezh2 null embryonic
hearts. The direct binding of Ezh2 to the CpG island located in the
cis-regulatory sequence of the Hey2 gene and activation of the Hey2
promoter by Ezh2 raised the likelihood that Ezh2 directly
regulates Hey2 expression. Our observation that Ezh2 regulated
Hey2 gene expression adds another layer of complexity to our
understanding of this pathway, at least in the developing heart. Of
particular interest in the future is to probe whether Hey2 and Ezh2
can cooperatively govern cardiovascular developmental program
in vivo.
Our work further revealed that the crosstalk between Ezh2 and
the Notch pathway existed, at least on the promoters we tested.
Different levels of synergy between Ezh2 and Notch were observed
using different target promoters, indicating that the degree of
crosstalk between them may be context dependent. It appears that
Ezh2 may indirectly activate the target promoter via the Notch-
dependent pathway, because together with Notch2-ic, Ezh2
elevated a Notch reporter that presumably does not have any
potential Ezh2 binding element(s). However, in Ezh2 null mice,
there was no significant change in the transcription level of most
Notch downstream targets; thus, the in vivo relevance of the
functional interaction between Ezh2 and Notch signaling observed
in the promoter assays remains to be clarified. It will be interesting
to explore whether Ezh1could compensate for the loss of Ezh2, and
thereby, cooperate with Notch to maintain the normal expression
of the Notch signaling target genes. However, it is unlikely that
Ezh1 could replace the function of Ezh2 in normal cardiac
morphogenesis (see below).
Our microarray data showed that knockout of Ezh2 in heart
upregulated more genes (.600) than it downregulated (,200)
(Table S1 & S2, and data not shown), which is consistent with the
current belief that Ezh2 functions primarily as a repressor of target
gene expression. The major function of Ezh2 is to trimethylate
H3K27. As expected, deletion of the floxed SET domain of Ezh2
using Nkx2.5-cre resulted in a substantial decrease in H3K27Me3
in the heart. The residual H3K27Me3 that was still seen after Ezh2
deletion was probably due to the presence of Ezh2 in the cells
where Nkx2.5-cre was inactive. Alternatively, the residual
H3K27Me3 could be ascribed to Ezh1, which was not affected
by the cardiac-specific deletion of Ezh2. Ezh1 was able to provide
partial functional compensation for the loss of Ezh2 in the
maintenance of stem cell identity [18], however, the severe
cardiovascular phenotypes and 100% immediate postnatal demise
of Ezh2
fl/fl:Nkx2.5-cre+ mice argued that very little or no functional
redundancy between Ezh1 and Ezh2 exists in the context of
cardiac structural morphogenesis.
Finally, another interesting aspect is how Ezh2 activity is
regulated and how that regulation affects cardiogenesis. One of the
major regulatory mechanisms that modulate Ezh2 function is
posttranslational modification, i.e. phosphorylation [57,58]. More
recently, Ezh2 was identified as a target of SUMO modification
[59], a covalent conjugation process that is mediated by a series of
enzymes and is emerging as an important regulator of cardiac
development and function [60,61]. How these modulations affect
Ezh2 function, and consequently, impinge on embryonic heart
development is an interesting topic to explore in the future.
Supporting Information
Table S1 Significantly up-regulated genes in the Ezh2
mutant hearts at E16.5 as analyzed by microarray (n=3
for WT and Ezh2-cKO, respectively). The threshold of fold
change was set at.or=1.5.
(XLS)
Table S2 Significantly down-regulated genes in the
Ezh2 mutant hearts at E16.5 as analyzed by microarray
(n=3 for WT and Ezh2-cKO, respectively). The threshold
of fold change was set at,or=0.75.
(XLS)
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